Form Type:  CT ORDER
Filing Date:  3/13/2018 
CIK:  0001348911 
BUILDING 200, STE. 2203
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  (857) 999-0075 
Fiscal Year:  04/30 
Last Trade
Last Trade: 
0.45 (5.28%)  
Trade Time: 
Jun 22  
Market Cap: 
Trade KALV now with 

© 2018  
Description of Business
We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors. Our first product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema ("HAE") and diabetic macular edema ("DME"). We apply our insights into the chemistry of proteases and, with our current programs, the biology of the plasma kallikrein system, to develop molecules with properties such as selectivity, potency and bioavailability that we believe will make them successful treatments for disease. There is good evidence that inhibition of plasma kallikrein is able to treat HAE. Currently marketed therapies are all administered by injection and we anticipate considerable potential for orally delivered, small molecule treatments.
Register and access this filing in: